Medtronic (MDT) Expected to Announce Earnings on Tuesday

Medtronic (NYSE:MDT) is projected to announce its Q3 2026 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $1.33 per share and revenue of $8.8950 billion for the quarter. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:00 AM ET.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the firm posted $1.26 earnings per share. Medtronic’s revenue was up 6.6% compared to the same quarter last year. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Medtronic Price Performance

Shares of NYSE:MDT opened at $101.69 on Tuesday. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The business has a 50-day simple moving average of $99.37 and a two-hundred day simple moving average of $96.22. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The firm has a market cap of $130.37 billion, a price-to-earnings ratio of 27.41, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s payout ratio is currently 76.55%.

Institutional Trading of Medtronic

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Florida Financial Advisors LLC lifted its position in shares of Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock valued at $234,000 after buying an additional 122 shares in the last quarter. CYBER HORNET ETFs LLC lifted its holdings in Medtronic by 3.9% during the third quarter. CYBER HORNET ETFs LLC now owns 3,502 shares of the medical technology company’s stock valued at $334,000 after purchasing an additional 130 shares in the last quarter. Binnacle Investments Inc lifted its holdings in Medtronic by 7.0% during the second quarter. Binnacle Investments Inc now owns 2,278 shares of the medical technology company’s stock valued at $199,000 after purchasing an additional 150 shares in the last quarter. Sculati Wealth Management LLC boosted its position in shares of Medtronic by 1.1% in the third quarter. Sculati Wealth Management LLC now owns 18,254 shares of the medical technology company’s stock worth $1,739,000 after purchasing an additional 190 shares during the period. Finally, Resurgent Financial Advisors LLC increased its stake in shares of Medtronic by 4.2% in the third quarter. Resurgent Financial Advisors LLC now owns 5,494 shares of the medical technology company’s stock worth $523,000 after purchasing an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

MDT has been the topic of a number of research analyst reports. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Barclays boosted their target price on shares of Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a research note on Thursday, January 8th. TD Cowen restated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Wells Fargo & Company assumed coverage on Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price on the stock. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.21.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).